Research programme : cancer therapeutics - Genor Bio
Latest Information Update: 15 Mar 2023
At a glance
- Originator Genor Biopharma
- Class Antibodies; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 27 Feb 2023 Early research in Cancer in China (Parenteral) prior to February 2023 (Genor Biopharma website, February 2023)